Biological E. In-licenses Two Takeda Vaccines for India/China

India's Biological E. Limited in-licensed rights to two Takeda vaccines for India, China and low/middle income countries. Biological E intends to combine the vaccines, which protect against measles and pertussis, with other vaccines. Takeda positioned the licensing as a community health initiative for low/middle income countries.  It said the agreements would expedite the development and delivery of affordable combination vaccines that address unmet needs, a goal that BE shares with Takeda. Terms of the licensings were not disclosed. More details.... Stock Symbol: (TSE: 4502) Share this with colleagues: // //